LLY Forex News

Eli Lilly CFO Anat Ashkenazi Resigns

Eli Lilly CFO Anat Ashkenazi Resigns

Eli Lilly and Co. (LLY) announced Wednesday that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry.
RTTNews | 1 day ago
Eli Lilly Boosts FY24 Outlook - Update

Eli Lilly Boosts FY24 Outlook - Update

While reporting financial results for the first quarter on Tuesday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2024, primarily driven by the strong performance of Mounjaro and Zepbound and greater visibility into the company's production expansion for the remainder of the year.
RTTNews | 37 days ago
Eli Lilly Q4 Results Top Estimates

Eli Lilly Q4 Results Top Estimates

Drugmaker Eli Lilly reported Tuesday a profit for the fourth quarter that grew 13 percent from last year, reflecting strong Mounjaro sales and higher realized prices. Both adjusted earnings per share and revenues topped analysts' expectations. The company also provided strong revenue guidance for the full-year 2024.
RTTNews | 121 days ago
Eli Lilly Sues Clinics Over Unauthorized Mounjaro Drug Sale

Eli Lilly Sues Clinics Over Unauthorized Mounjaro Drug Sale

Eli Lilly has filed lawsuits against several medical spas, wellness centers and compounding pharmacies for unauthorized sale of diabetes drug Mounjaro (tirzepatide). These clinics allegedly use the drug for weight loss treatment. Mounjaro, approved for type 2 diabetes, is only available from and manufactured by Lilly. They are commercially available in a pre-filled single-dose pen only.
RTTNews | 260 days ago
Eli Lilly Says LIBRETTO-531 Study Evaluating Retevmo Meets Primary Endpoint

Eli Lilly Says LIBRETTO-531 Study Evaluating Retevmo Meets Primary Endpoint

Eli Lilly and Co. (LLY) announced Tuesday topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the multikinase inhibitors (MKIs) cabozantinib or vandetanib as an initial treatment for patients with advanced or metastatic rearranged during transfection(RET)-mutant medullary thyroid cancer (MTC).
RTTNews | 289 days ago
Eli Lilly Boosts Outlook As Q2 Results Top Estimates; Stock Up 11%

Eli Lilly Boosts Outlook As Q2 Results Top Estimates; Stock Up 11%

Drugmaker Eli Lilly and Co. reported Tuesday a profit for the second quarter that surged 85 percent from last year, reflecting strong Mounjaro sales and a solid performance from growth products. Both adjusted earnings per share and revenues topped analysts' expectations. The company also raised its adjusted earnings and revenue guidance for the full-year 2023.
RTTNews | 303 days ago
Eli Lilly Boosts FY23 Outlook - Update

Eli Lilly Boosts FY23 Outlook - Update

While reporting financial results for the second quarter on Tuesday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2023.
RTTNews | 303 days ago